Cargando…

Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease

BACKGROUND: Lipoprotein(a) (Lp(a)) concentrations are a major independent risk factor for coronary artery disease (CAD) and are mainly determined by variation in LPA. Up to 70% of the LPA coding sequence is located in the hyper-variable kringle IV type 2 (KIV-2) region. It is hardly accessible by co...

Descripción completa

Detalles Bibliográficos
Autores principales: Schachtl-Riess, Johanna F., Kheirkhah, Azin, Grüneis, Rebecca, Di Maio, Silvia, Schoenherr, Sebastian, Streiter, Gertraud, Losso, Jamie Lee, Paulweber, Bernhard, Eckardt, Kai-Uwe, Köttgen, Anna, Lamina, Claudia, Kronenberg, Florian, Coassin, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613585/
https://www.ncbi.nlm.nih.gov/pubmed/34325833
http://dx.doi.org/10.1016/j.jacc.2021.05.037
_version_ 1783605496716984320
author Schachtl-Riess, Johanna F.
Kheirkhah, Azin
Grüneis, Rebecca
Di Maio, Silvia
Schoenherr, Sebastian
Streiter, Gertraud
Losso, Jamie Lee
Paulweber, Bernhard
Eckardt, Kai-Uwe
Köttgen, Anna
Lamina, Claudia
Kronenberg, Florian
Coassin, Stefan
author_facet Schachtl-Riess, Johanna F.
Kheirkhah, Azin
Grüneis, Rebecca
Di Maio, Silvia
Schoenherr, Sebastian
Streiter, Gertraud
Losso, Jamie Lee
Paulweber, Bernhard
Eckardt, Kai-Uwe
Köttgen, Anna
Lamina, Claudia
Kronenberg, Florian
Coassin, Stefan
author_sort Schachtl-Riess, Johanna F.
collection PubMed
description BACKGROUND: Lipoprotein(a) (Lp(a)) concentrations are a major independent risk factor for coronary artery disease (CAD) and are mainly determined by variation in LPA. Up to 70% of the LPA coding sequence is located in the hyper-variable kringle IV type 2 (KIV-2) region. It is hardly accessible by conventional technologies, but may contain functional variants. OBJECTIVES: This study sought to investigate the new, very frequent splicing variant KIV-2 4733G>A on Lp(a) and CAD. METHODS: We genotyped 4733G>A in the GCKD (German Chronic Kidney Disease) study (n = 4,673) by allele-specific polymerase chain reaction, performed minigene assays, identified proxy single nucleotide polymorphisms and used them to characterize its effect on CAD by survival analysis in UK Biobank (n = 440,234). Frequencies in ethnic groups were assessed in the 1000 Genomes Project. RESULTS: The 4733G>A variant (38.2% carrier frequency) was found in most isoform sizes. It reduces allelic expression without abolishing protein production, lowers Lp(a) by 13.6 mg/dL (95% CI: 12.5-14.7; P < 0.0001) and is the strongest variance-explaining factor after the smaller isoform. Splicing of minigenes was modified. Compound heterozygosity (4.6% of the population) for 4733G>A and 4925G>A, another KIV-2 splicing mutation, reduces Lp(a) by 31.8 mg/dL and most importantly narrows the interquartile range by 9-fold (from 42.1 to 4.6 mg/dL) when compared to the wild type. In UK Biobank 4733G>A alone and compound heterozygosity with 4925G>A reduced HR for CAD by 9% (95% CI: 7%-11%) and 12% (95% CI: 7%-16%) (both P < 0.001). Frequencies in ethnicities differ notably. CONCLUSIONS: Functional variants in the previously inaccessible LPA KIV-2 region cooperate in determining Lp(a) variance and CAD risk. Even a moderate but lifelong genetic Lp(a) reduction translates to a noticeable CAD risk reduction. (J Am Coll Cardiol 2021;78:437–49)
format Online
Article
Text
id pubmed-7613585
institution National Center for Biotechnology Information
language English
publishDate 2021
record_format MEDLINE/PubMed
spelling pubmed-76135852022-09-15 Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease Schachtl-Riess, Johanna F. Kheirkhah, Azin Grüneis, Rebecca Di Maio, Silvia Schoenherr, Sebastian Streiter, Gertraud Losso, Jamie Lee Paulweber, Bernhard Eckardt, Kai-Uwe Köttgen, Anna Lamina, Claudia Kronenberg, Florian Coassin, Stefan J Am Coll Cardiol Article BACKGROUND: Lipoprotein(a) (Lp(a)) concentrations are a major independent risk factor for coronary artery disease (CAD) and are mainly determined by variation in LPA. Up to 70% of the LPA coding sequence is located in the hyper-variable kringle IV type 2 (KIV-2) region. It is hardly accessible by conventional technologies, but may contain functional variants. OBJECTIVES: This study sought to investigate the new, very frequent splicing variant KIV-2 4733G>A on Lp(a) and CAD. METHODS: We genotyped 4733G>A in the GCKD (German Chronic Kidney Disease) study (n = 4,673) by allele-specific polymerase chain reaction, performed minigene assays, identified proxy single nucleotide polymorphisms and used them to characterize its effect on CAD by survival analysis in UK Biobank (n = 440,234). Frequencies in ethnic groups were assessed in the 1000 Genomes Project. RESULTS: The 4733G>A variant (38.2% carrier frequency) was found in most isoform sizes. It reduces allelic expression without abolishing protein production, lowers Lp(a) by 13.6 mg/dL (95% CI: 12.5-14.7; P < 0.0001) and is the strongest variance-explaining factor after the smaller isoform. Splicing of minigenes was modified. Compound heterozygosity (4.6% of the population) for 4733G>A and 4925G>A, another KIV-2 splicing mutation, reduces Lp(a) by 31.8 mg/dL and most importantly narrows the interquartile range by 9-fold (from 42.1 to 4.6 mg/dL) when compared to the wild type. In UK Biobank 4733G>A alone and compound heterozygosity with 4925G>A reduced HR for CAD by 9% (95% CI: 7%-11%) and 12% (95% CI: 7%-16%) (both P < 0.001). Frequencies in ethnicities differ notably. CONCLUSIONS: Functional variants in the previously inaccessible LPA KIV-2 region cooperate in determining Lp(a) variance and CAD risk. Even a moderate but lifelong genetic Lp(a) reduction translates to a noticeable CAD risk reduction. (J Am Coll Cardiol 2021;78:437–49) 2021-08-03 /pmc/articles/PMC7613585/ /pubmed/34325833 http://dx.doi.org/10.1016/j.jacc.2021.05.037 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY LICENSE https://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Schachtl-Riess, Johanna F.
Kheirkhah, Azin
Grüneis, Rebecca
Di Maio, Silvia
Schoenherr, Sebastian
Streiter, Gertraud
Losso, Jamie Lee
Paulweber, Bernhard
Eckardt, Kai-Uwe
Köttgen, Anna
Lamina, Claudia
Kronenberg, Florian
Coassin, Stefan
Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease
title Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease
title_full Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease
title_fullStr Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease
title_full_unstemmed Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease
title_short Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease
title_sort frequent lpa kiv-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613585/
https://www.ncbi.nlm.nih.gov/pubmed/34325833
http://dx.doi.org/10.1016/j.jacc.2021.05.037
work_keys_str_mv AT schachtlriessjohannaf frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT kheirkhahazin frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT gruneisrebecca frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT dimaiosilvia frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT schoenherrsebastian frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT streitergertraud frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT lossojamielee frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT paulweberbernhard frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT eckardtkaiuwe frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT kottgenanna frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT laminaclaudia frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT kronenbergflorian frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT coassinstefan frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease
AT frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease